Boston Scientific traded at $76.26 this Friday February 6th, decreasing $1.38 or 1.78 percent since the previous trading session. Looking back, over the last four weeks, Boston Scientific lost 22.70 percent. Over the last 12 months, its price fell by 27.54 percent. Looking ahead, we forecast Boston Scientific to be priced at 90.65 by the end of this quarter and at 82.53 in one year, according to Trading Economics global macro models projections and analysts expectations.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by businesses such Interventional Cardiology, Peripheral Interventions, Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health, Neuromodulation and Specialty Pharmaceuticals. It operates in three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. MedSurg consists of Endoscopy and Urology and Pelvic Health businesses. Rhythm segment consists of Cardiac Rhythm Management, Electrophysiology and Neuromodulation businesses. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.